Defence Therapeutics Stock Price To Earning
| DTCFF Stock | USD 0.41 0.01 2.50% |
Defence Therapeutics fundamentals help investors to digest information that contributes to Defence Therapeutics' financial success or failures. It also enables traders to predict the movement of Defence OTC Stock. The fundamental analysis module provides a way to measure Defence Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Defence Therapeutics otc stock.
Defence |
Defence Therapeutics OTC Stock Price To Earning Analysis
Defence Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Defence Therapeutics has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earning for all United States stocks is 100.0% higher than that of the company.
Defence Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Defence Therapeutics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Defence Therapeutics could also be used in its relative valuation, which is a method of valuing Defence Therapeutics by comparing valuation metrics of similar companies.Defence Therapeutics is currently under evaluation in price to earning category among its peers.
Defence Fundamentals
| Return On Equity | -4.15 | |||
| Return On Asset | -1.79 | |||
| Current Valuation | 60.32 M | |||
| Shares Outstanding | 37.85 M | |||
| Shares Owned By Insiders | 5.26 % | |||
| Price To Book | 36.71 X | |||
| EBITDA | (7.32 M) | |||
| Net Income | (7.34 M) | |||
| Cash And Equivalents | 506.7 K | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 0.61 X | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (6.04 M) | |||
| Earnings Per Share | (0.15) X | |||
| Market Capitalization | 143.45 M | |||
| Total Asset | 719.67 K | |||
| Z Score | -33.0 | |||
| Net Asset | 719.67 K |
About Defence Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Defence Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Defence Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Defence Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Defence OTC Stock
Defence Therapeutics financial ratios help investors to determine whether Defence OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Defence with respect to the benefits of owning Defence Therapeutics security.